262 related articles for article (PubMed ID: 12659767)
41. Design, synthesis and systematic evaluation of cytotoxic 3-heteroarylisoquinolinamines as topoisomerases inhibitors.
My Van HT; Woo H; Jeong HM; Khadka DB; Yang SH; Zhao C; Jin Y; Lee ES; Youl Lee K; Kwon Y; Cho WJ
Eur J Med Chem; 2014 Jul; 82():181-94. PubMed ID: 24904965
[TBL] [Abstract][Full Text] [Related]
42. Various inhibitors of DNA topoisomerases diminish repair-specific DNA incision in UV-irradiated human fibroblasts.
Thielmann HW; Popanda O; Gersbach H; Gilberg F
Carcinogenesis; 1993 Nov; 14(11):2341-51. PubMed ID: 8242865
[TBL] [Abstract][Full Text] [Related]
43. Cytotoxicity and DNA topoisomerase inhibitory activity of constituents isolated from the fruits of Evodia officinalis.
Xu ML; Li G; Moon DC; Lee CS; Woo MH; Lee ES; Jahng Y; Chang HW; Lee SH; Son JK
Arch Pharm Res; 2006 Jul; 29(7):541-7. PubMed ID: 16903072
[TBL] [Abstract][Full Text] [Related]
44. DNA topoisomerases as targets for the anticancer drug TAS-103: primary cellular target and DNA cleavage enhancement.
Byl JA; Fortune JM; Burden DA; Nitiss JL; Utsugi T; Yamada Y; Osheroff N
Biochemistry; 1999 Nov; 38(47):15573-9. PubMed ID: 10569941
[TBL] [Abstract][Full Text] [Related]
45. DNA topoisomerase I-mediated formation of structurally modified DNA duplexes. Effects of metal ions and topoisomerase I inhibitors.
Wang X; Henningfeld KA; Hecht SM
Biochemistry; 1998 Feb; 37(8):2691-700. PubMed ID: 9485420
[TBL] [Abstract][Full Text] [Related]
46. Topoisomerase I-mediated DNA cleavage as a guide to the development of antitumor agents derived from the marine alkaloid lamellarin D: triester derivatives incorporating amino acid residues.
Tardy C; Facompré M; Laine W; Baldeyrou B; García-Gravalos D; Francesch A; Mateo C; Pastor A; Jiménez JA; Manzanares I; Cuevas C; Bailly C
Bioorg Med Chem; 2004 Apr; 12(7):1697-712. PubMed ID: 15028262
[TBL] [Abstract][Full Text] [Related]
47. Topoisomerase I inhibition and cytotoxicity of 5-bromo- and 5-phenylterbenzimidazoles.
Rangarajan M; Kim JS; Sim SP; Liu A; Liu LF; Lavoie EJ
Bioorg Med Chem; 2000 Nov; 8(11):2591-600. PubMed ID: 11092544
[TBL] [Abstract][Full Text] [Related]
48. Synthesis and evaluation of 9-benzylideneamino derivatives of homocamptothecin as potent inhibitors of DNA topoisomerase I.
Guo W; Miao Z; Sheng C; Yao J; Feng H; Zhang W; Zhu L; Liu W; Cheng P; Zhang J; Che X; Wang W; Luo C; Xu Y
Eur J Med Chem; 2010 Jun; 45(6):2223-8. PubMed ID: 20202723
[TBL] [Abstract][Full Text] [Related]
49. Structural considerations of NK109, an antitumor benzo[c]phenanthridine alkaloid.
Nakanishi T; Suzuki M; Saimoto A; Kabasawa T
J Nat Prod; 1999 Jun; 62(6):864-7. PubMed ID: 10395504
[TBL] [Abstract][Full Text] [Related]
50. Quaternary benzo[c]phenanthridine alkaloids as inhibitors of aminopeptidase N and dipeptidyl peptidase IV.
Sedo A; Vlasicová K; Barták P; Vespalec R; Vicar J; Simánek V; Ulrichová J
Phytother Res; 2002 Feb; 16(1):84-7. PubMed ID: 11807974
[TBL] [Abstract][Full Text] [Related]
51. Development of 13H-benzo[f]chromeno[4,3-b][1,7]naphthyridines and their salts as potent cytotoxic agents and topoisomerase I/IIα inhibitors.
Arepalli SK; Lee C; Sim S; Lee K; Jo H; Jun KY; Kwon Y; Kang JS; Jung JK; Lee H
Bioorg Med Chem; 2018 Oct; 26(18):5181-5193. PubMed ID: 30253887
[TBL] [Abstract][Full Text] [Related]
52. BN 80927: a novel homocamptothecin with inhibitory activities on both topoisomerase I and topoisomerase II.
Lavergne O; Harnett J; Rolland A; Lanco C; Lesueur-Ginot L; Demarquay D; Huchet M; Coulomb H; Bigg DC
Bioorg Med Chem Lett; 1999 Sep; 9(17):2599-602. PubMed ID: 10498216
[TBL] [Abstract][Full Text] [Related]
53. Inhibitory properties of antitumor prostaglandins against topoisomerases.
Suzuki K; Uyeda M
Biosci Biotechnol Biochem; 2002 Aug; 66(8):1706-12. PubMed ID: 12353631
[TBL] [Abstract][Full Text] [Related]
54. Inhibition of topoisomerases by fatty acids.
Suzuki K; Shono F; Kai H; Uno T; Uyeda M
J Enzyme Inhib; 2000; 15(4):357-66. PubMed ID: 10995067
[TBL] [Abstract][Full Text] [Related]
55. Rational design, synthesis, and evaluation of novel 2,4-Chloro- and Hydroxy-Substituted diphenyl Benzofuro[3,2-b]Pyridines: Non-intercalative catalytic topoisomerase I and II dual inhibitor.
Park S; Thapa Magar TB; Kadayat TM; Lee HJ; Bist G; Shrestha A; Lee ES; Kwon Y
Eur J Med Chem; 2017 Feb; 127():318-333. PubMed ID: 28068603
[TBL] [Abstract][Full Text] [Related]
56. F 11782, a novel epipodophylloid non-intercalating dual catalytic inhibitor of topoisomerases I and II with an original mechanism of action.
Perrin D; van Hille B; Barret JM; Kruczynski A; Etiévant C; Imbert T; Hill BT
Biochem Pharmacol; 2000 Apr; 59(7):807-19. PubMed ID: 10718339
[TBL] [Abstract][Full Text] [Related]
57. Total synthesis of oxyfagaronine, phenolic benzo[c]phenanthridine and general synthetic way of 2,3,7,8- and 2,3,8,9-tetrasubstituted benzo[c]phenanthridine alkaloids.
Le TN; Cho WJ
Chem Pharm Bull (Tokyo); 2006 Apr; 54(4):476-80. PubMed ID: 16595948
[TBL] [Abstract][Full Text] [Related]
58. Novel angular benzophenazines: dual topoisomerase I and topoisomerase II inhibitors as potential anticancer agents.
Vicker N; Burgess L; Chuckowree IS; Dodd R; Folkes AJ; Hardick DJ; Hancox TC; Miller W; Milton J; Sohal S; Wang S; Wren SP; Charlton PA; Dangerfield W; Liddle C; Mistry P; Stewart AJ; Denny WA
J Med Chem; 2002 Jan; 45(3):721-39. PubMed ID: 11806724
[TBL] [Abstract][Full Text] [Related]
59. Substitution at the F-ring N-imide of the indolocarbazole antitumor drug NB-506 increases the cytotoxicity, DNA binding, and topoisomerase I inhibition activities.
Bailly C; Qu X; Chaires JB; Colson P; Houssier C; Ohkubo M; Nishimura S; Yoshinari T
J Med Chem; 1999 Jul; 42(15):2927-35. PubMed ID: 10425102
[TBL] [Abstract][Full Text] [Related]
60. Synthesis and PC3 androgen-independent prostate cells antiproliferative effect of fagaronine derivatives.
Vanquelef E; Hélesbeux JJ; Duval O; Debiton E; Barthomeuf C; Jarry C; Forfar I; Richomme P
J Enzyme Inhib Med Chem; 2007 Oct; 22(5):647-54. PubMed ID: 18035833
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
